Adagene (ADAG) Receivables (2019 - 2026)
Adagene (ADAG) posted quarterly Receivables of $7.5 million for Q4 2021, up 385.05% quarter-over-quarter from $1.5 million in Q2 2021.
Powered by 
Analysis
Adagene (ADAG) Receivables (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Receivables for 2 consecutive years, with $7.5 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Receivables changed N/A year-over-year to $7.5 million; the TTM figure through Dec 2021 stood at $7.5 million (changed N/A YoY), while the FY2021 annual figure was $7.5 million, changed N/A from the prior year.
- Receivables rose to $7.5 million in Q4 2021 per ADAG's latest filing, from $1.5 million in the prior quarter.
- Across five years, Receivables topped out at $7.5 million in Q4 2021 and bottomed at $1.5 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 160.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.06 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 215.33 Mn |
| 10 | Adagene | 211.24 Mn | 211.24 Mn | - | 153,025.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 153,025.00 |
| Dec 31, 2021 | -1.37 Mn |
| Jun 30, 2021 | 1.55 Mn |
| Dec 31, 2019 | -224,253.00 |